Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy

Güner, Rahmet; Hasanoğlu, İmran; Keske, Şiran; Kalem, Ayşe Kaya; Taşyaran, Mehmet A.

doi:10.1007/s15010-011-0161-1

Cited by 38 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tigecycline has been used since 2007 and resistance to this antibiotic developed rapidly in our hospital (Table 3). We think that this situation may be due to the intensive usage of tigecycline in the treatment of nonapproved indications, such as nosocomial pneumonia, because of the limited availability of colistin until 2010 (23). The tigecycline resistance rates were reported as 0.9% and 0% in the studies performed by Özdemir et al and Mansur et al in 2008 (14,15 (17).…”

Section: Discussionmentioning

confidence: 99%

Increasing resistance of nosocomial Acinetobacter baumannii: are we going to be defeated?

Güven¹,

Yılmaz²,

Güner³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

In this work we have used the Viril theorem to investigate the dynamical stability of Hickson compact groups of galaxies. The average luminous mass of the galaxies member is approximately 1.3 ×0 11 M and average total luminous mass of group is approximately 4.6 ×0 11 M . The virial theorem has used to estimate the virial mass. The average Virial mass of group of galaxies is approximately 6.3 ×0 13 M This is attributed to the presence of large amount of dark matter which is more than 90% in this group. Hickson compact groups of galaxies are unstable system due to the virial to luminous masses ratio.

show abstract

Section: Discussionmentioning

confidence: 99%

Increasing resistance of nosocomial Acinetobacter baumannii: are we going to be defeated?

Güven¹,

Yılmaz²,

Güner³

et al. 2014

Turk J Med Sci

View full text Add to dashboard Cite

show abstract

“…Remaining agents with activity against carbapenemase producers include polymyxins (colistin and polymyxin B), tigecycline, and fosfomycin; however, resistance to these agents has been described as well (72). Table 2 summarizes some comparative clinical studies evaluating monotherapy and combination therapy for infections with highly resistant Gram-negative bacteria (52,73,74,103,150,154,243). These regimens are generally considered "salvage therapy" for MDRGN infections.…”

Section: Other Antibiotic Combinations For Infections With Multidrug-mentioning

confidence: 99%

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

2012

View full text Add to dashboard Cite

SUMMARY Combination antibiotic therapy for invasive infections with Gram-negative bacteria is employed in many health care facilities, especially for certain subgroups of patients, including those with neutropenia, those with infections caused by Pseudomonas aeruginosa , those with ventilator-associated pneumonia, and the severely ill. An argument can be made for empiric combination therapy, as we are witnessing a rise in infections caused by multidrug-resistant Gram-negative organisms. The wisdom of continued combination therapy after an organism is isolated and antimicrobial susceptibility data are known, however, is more controversial. The available evidence suggests that the greatest benefit of combination antibiotic therapy stems from the increased likelihood of choosing an effective agent during empiric therapy, rather than exploitation of in vitro synergy or the prevention of resistance during definitive treatment. In this review, we summarize the available data comparing monotherapy versus combination antimicrobial therapy for the treatment of infections with Gram-negative bacteria.

show abstract

“…Therefore, several investigators have warned against using tigecycline monotherapy in VAP patients. Guner and associates reported the efficacy of tigecycline in 33 patients (19 with VAP) with carbapenem-resistant Acinetobacter spp., usually when used as part of a combination regimen [70]. In an exploratory study that tried to improve the efficacy of tigecycline against Acinetobacter spp.…”

Section: Role Of Tigecycline In Treatment Of Vap Patients With a Baumentioning

confidence: 99%

Ventilator-associated pneumonia: present understanding and ongoing debates

2014

View full text Add to dashboard Cite

The morbidity and mortality related to VAP remain high and, in the absence of a gold standard test for diagnosis, suspected VAP patients should be started on antibiotics based on recommendations per the 2005 ATS guidelines and knowledge of local antibiotic susceptibility patterns. Using a combination of clinical severity scores, biomarkers, and cultures might help with reducing the duration of therapy and achieving antibiotic de-escalation.

show abstract

Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy

Cited by 38 publications

References 17 publications

Increasing resistance of nosocomial Acinetobacter baumannii: are we going to be defeated?

Increasing resistance of nosocomial Acinetobacter baumannii: are we going to be defeated?

Combination Therapy for Treatment of Infections with Gram-Negative Bacteria

Ventilator-associated pneumonia: present understanding and ongoing debates

Contact Info

Product

Resources

About